Inhibrx Biosciences Inc (INBX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2024 | 03-2024 | 12-2023 | 09-2023 | 06-2023 | |
| Sales | 100 | 0 | 1,634 | 119 | 30 |
| Gross Profit | 100 | N/A | 1,634 | 119 | 30 |
| Operating Expenses | 160,998 | 73,825 | 89,923 | 45,946 | 41,369 |
| Operating Income | -160,898 | -73,825 | -88,289 | -45,827 | -41,339 |
| Interest Expense | 5,361 | 8,130 | 8,223 | 8,149 | 7,905 |
| Other Income | 2,024,272 | 3,245 | 4,538 | 2,189 | 2,197 |
| Pre-tax Income | 1,858,013 | -78,710 | -91,974 | -51,787 | -47,047 |
| Income Tax | 2 | N/A | -4 | 2 | 5 |
| Net Income Continuous | 1,858,011 | -78,710 | -93,604 | -51,789 | -47,052 |
| Net Income | $1,858,011 | $-78,710 | $-93,604 | $-51,789 | $-47,052 |
| EPS Basic Total Ops | 127.10 | -1.44 | -1.82 | -1.10 | -1.08 |
| EPS Basic Continuous Ops | 127.10 | -1.44 | -1.82 | -1.10 | -1.08 |
| EPS Diluted Total Ops | 125.48 | -1.44 | -1.82 | -1.10 | -1.08 |
| EPS Diluted Continuous Ops | 125.48 | -1.44 | -1.82 | -1.10 | -1.08 |
| EPS Diluted Before Non-Recurring Items | 125.48 | N/A | -1.73 | -1.10 | -1.08 |
| EBITDA(a) | $-160,422 | $-72,223 | $-86,744 | $-44,284 | $-39,828 |